Boehringer Ingelheim

This study will look at how well the drug Jardiance works compared to usual heart failure treatments in about 5,000 people in China with a type of heart failure called HFrEF. The goal is to see if Jardiance is better at preventing hospital stays or death from heart problems. Part…

This study tests a new targeted drug, zongertinib, combined with chemotherapy (with or without pembrolizumab) in people with advanced HER2-mutant non-squamous lung cancer who haven't had treatment before. About 60 adults will be randomly assigned to one of two treatment groups. T…

This study tests whether adding the experimental drug obrixtamig to standard chemotherapy helps people with advanced extrapulmonary neuroendocrine cancer live longer. About 390 adults will be randomly assigned to receive either the combination or chemo alone. The goal is to see i…

This study tests a medicine called nerandomilast in children aged 2 to 17 with fibrosing interstitial lung disease, a condition where lung tissue becomes scarred and stiff. The goal is to see if the drug is safe and helps lung function. Some children receive the drug, others a pl…

This study tests a new medicine called nerandomilast in adults with a type of lung scarring (fibrosing ILD) that is not IPF. About 466 participants will take either the drug or a placebo for at least 52 weeks to see if it helps slow the decline in lung function. The goal is to ke…

This early-phase study tests a new drug, BI 1831169, combined with an existing cancer immunotherapy (anti-PD1 antibody) in Japanese adults with advanced solid tumors that have spread or not responded to prior treatments. The main goal is to find the highest safe dose of BI 183116…

This study tests a new medicine called BI 3812465 for people with diabetic macular edema, a condition that causes swelling in the center of the eye and can lead to vision loss. The trial has two parts: first, a small group gets low to high doses to check safety; then, a larger gr…

This study tests a new oral medication, nerandomilast, for people with systemic sclerosis, a chronic autoimmune disease that causes skin thickening and organ damage. About 448 adults will be randomly assigned to receive either the drug or a placebo twice daily for up to 4 years. …

This study will observe about 3,000 Chinese adults with a type of heart failure called HFpEF who are starting the drug Jardiance. Researchers want to see how effective and safe the drug is in everyday medical practice, not in a controlled lab setting. The study will track heart-r…

This early-stage study is testing a new drug called BI 3814916 in 136 healthy adults aged 18 to 65. The main goal is to see if the drug is safe and how the body processes it. Participants will receive either the drug or a placebo, and no direct health benefit is expected.

This early-stage study will give verducatib pills daily for 4 weeks to 12 healthy Chinese adults aged 18-55. The goal is to measure how the drug moves through the body and check for any side effects. Participants will not receive any direct medical benefit, but results will help …